Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ACS Announces New Editor-in-Chief of Chemical Research in Toxicology

Published: Friday, July 20, 2012
Last Updated: Friday, July 20, 2012
Bookmark and Share
Stephen S. Hecht will take over as Editor-in-Chief of Chemical Research in Toxicology in January 2013.

The American Chemical Society (ACS) has announced that Stephen S. Hecht, Ph.D., will take over as Editor-in-Chief of Chemical Research in Toxicology in January 2013.

Hecht is the Winston R. and Maxine H. Wallin Land Grant Professor of Cancer Prevention and American Cancer Society Professor at the Masonic Cancer Center at the University of Minnesota, Minneapolis, and currently serves as an Associate Editor of the Journal of Medicinal Chemistry.

Hecht will succeed Lawrence J. Marnett, Ph.D., who will retire from the journal at the end of this year.

Marnett, Mary Geddes Stahlman Professor of Cancer Research and professor of biochemistry, chemistry and pharmacology at Vanderbilt University, has served as Editor-in-Chief of Chemical Research in Toxicology since he helped found the journal in 1988.

Marnett will assist with the transition and remain with the journal in his current role through the end of 2012.

“Professor Hecht’s distinguished career, his experience in both chemical toxicology and medicinal chemistry and his vision for the future of the journal will serve him well as the editor of Chemical Research in Toxicology,” said Susan King, senior vice president of the Journals Publishing Group at ACS.

Hecht, elected an ACS Fellow in 2009, received his B.S. in chemistry from Duke University in 1964 and a Ph.D. in organic chemistry from the Massachusetts Institute of Technology in 1968.

He joined the Masonic Cancer Center in 1996, where his research interests center on elucidating the mechanisms of chemical carcinogenesis in humans, including those related to tobacco-induced cancer.

His group looks for carcinogen biomarkers and applies them to molecular epidemiology and cancer prevention, and more specifically, to the prevention of lung and esophageal cancer.

Outgoing Editor Marnett said of Hecht, “He is the second-leading author over the past 25 years of all the authors who have published in the journal. His work is very high quality, very rigorous and very chemical. He appreciates what the journal has meant in the community, and I know he’s very interested in seeing it flourish.”

Hecht has received numerous awards, including the Joseph Cullen Award from the American Society of Preventive Oncology in 2012, the Founders’ Award from the ACS Division of Chemical Toxicology in 2009 and the American Association for Cancer Research-Cancer Research and Prevention Foundation Award for Excellence in Cancer Prevention Research in 2006.

Chemical Research in Toxicology publishes new and original research on the chemical basis of toxic responses in living organisms.

That research includes how cells and organisms respond to chemical or biological toxic agents and how those agents can lead to disease.

Chemical Research in Toxicology received 10,444 total citations in 2011. The journal also has a high Impact Factor of 3.779, as reported by the 2011 Journal Citation Reports® (Thomson Reuters, 2012).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Reprogramming Scorpion Venom
‘Twist of nature’ neutralizes toxin.
Tailoring a Suit for Tumor-Penetrating Cancer Meds
For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body.
Resurrecting an Abandoned Drug
Previously discarded drug shows promise in helping human cells in a lab dish fight off two different viruses.
Safer, Cheaper, Greener and More Efficient System for Organic Synthesis
The new medium not only supports organic synthesis it also produces considerably higher yields of product than pure organic solvents.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Collaboration to Develop Cancer Therapeutics
Major license agreement with Merck, enabled by Blavatnik Biomedical Accelerator, aims to develop therapy for most common form of acute leukemia.
Faster UVA Molecular Analysis Technology
There are people in the world – chemical engineers, astronomers, national defense scientists investigating an explosion – who need to know just what something is made of, down to the molecular level.
Scientists Synthesize Anti-Cancer Agent
A team led by Rice University synthetic organic chemist K.C. Nicolaou has developed a new process for the synthesis of a series of potent anti-cancer agents originally found in bacteria.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!